Venu Channamsetty, MD
Cardiovascular Disease · Bridgeport, CTNPI 1760516041
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $9,000 of the $12,254 with a category attached, or 73.4%. ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) accounts for 86.6% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2024 at $9,172 and has fallen 79.9% since, to $1,839 in 2025.
Across 86 payments — averaging $142.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$11K
- Pfizer$369
- Amgen$240
- Novartis$179
- Heartflow, Inc.$148
- E.r. Squibb & Sons, L.L.C.$141
- plus $563 from 13 others
Across 8 payments — averaging $1400.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim Pharma GmbH & Co.kg$7K
- Boehringer Ingelheim$4K
- Boehringer Ingelheim International GmbH$624
What the payments were for
- Consulting fees$4003%
- Speaking & faculty fees$9,00073%
- Travel & lodging$1,0008%
- Food & beverage$1,80315%
- Education$500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 14 | $10,615 |
| Pfizer | 15 | $369 |
| Amgen | 9 | $240 |
| Novartis | 9 | $179 |
| Heartflow, Inc. | 2 | $148 |
| E.r. Squibb & Sons, L.L.C. | 8 | $141 |
| Johnson & Johnson | 7 | $125 |
| Sanofi-aventis U.S. LLC | 6 | $112 |
| Boehringer Ingelheim | 3 | $53 |
| Regeneron Healthcare Solutions, Inc. | 2 | $53 |
| Merck | 2 | $43 |
| Boston Scientific | 2 | $40 |
| Medtronic | 1 | $34 |
| Actelion Pharmaceuticals US, Inc. | 1 | $24 |
| Lantheus Medical Imaging, Inc. | 1 | $22 |
| Irhythm Technologies, Inc. | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| AstraZeneca | 1 | $13 |
| Gilead | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,254 in reported general payments places this provider in the 85th percentile of 415 cardiovascular disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 38 | $37,257 |
| EntrestoSacubitril/Valsartan | 18 | $12,246 |
| XareltoRivaroxaban | 11 | $8,391 |
| Atorvastatin Calcium | 91 | $964 |
| Ranolazine ErRanolazine | 13 | $598 |
| Lisinopril | 56 | $300 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 12 | $299 |
| Rosuvastatin Calcium | 14 | $271 |
| Amlodipine Besylate | 88 | $261 |
| Valsartan | 19 | $219 |
| Furosemide | 50 | $212 |
| Carvedilol | 40 | $196 |
| Metoprolol Succinate | 26 | $182 |
| ClopidogrelClopidogrel Bisulfate | 21 | $168 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 17 | $155 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $369 | $37,25738 claims |
| NovartisEntresto | $179 | $12,24618 claims |
| Johnson & JohnsonXarelto | $125 | $8,39111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 415 cardiovascular disease providers in Connecticut.
Other cardiovascular disease in Bridgeport
- Stuart ZarichBridgeport$44K
- Doron AmirBridgeport$21K
- Nihar DesaiNew Haven$1.4M
- Brett NowlanBloomfield$798K
- Jeffery TestaniNew Haven$546K
- Carlos Mena-HurtadoNew Haven$460K
- Stephanie SaucierHartford$243K
- John ForrestNew Haven$164K
- Henry WardNew Haven$152K
- Ricardo CordidoHamden$135K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.